Clinical Efficacy and Immune Response of Recombinant Human Interferon α2b Vaginal Effervescent Tablets in the Treatment of High-risk HPV-induced Cervical Intraepithelial Neoplasia Grade 1
Abstract
High risk human papillomavirus (HR-HPV) induced cervical intraepithelial neoplasia grade 1 (CIN1) is a low-grade lesion closely associated with persistent viral infection, and clinical management remains challenging. This study aimed to investigate clinical efficacy and immune response of recombinant human interferon α2b vaginal effervescent tablets in CIN1 caused by HR-HPV.
In a retrospective study, 60 patients with HR-HPV and diagnosed with CIN1 from Shandong Provincial Hospital between December 2023 and December 2024 were divided into CT (n=30) and CR (n=30) groups, both groups were treated with conventional therapy, and recombinant human interferon α2b vaginal effervescent tablets were added to the CR group. The main assessment of both groups were inflammatory factor indicators, immune indicators, vaginal microenvironmental factors [hydrogen peroxide (H2O2) positivity, sialidase (SNA) positivity, leukocyte esterase (LE) positivity, N-acetylaminogalactosidase (NAG) positivity], HR-HPV conversion rate and clinical efficacy. Secondary outcomes included life quality scores, complication and adverse effect rates.
After treatment, the indicators of both groups were significantly different from the pre-treatment. The changes in inflammatory indicators, immune indicators, SNA positivity rate, LE positivity rate, HR-HPV conversion rate, clinical efficacy, life quality, complications, and adverse reactions in the CR group were better than those in the CT group. No marked discrepancy was found in the comparison of H2O2 positivity rate and NAG positivity rate between both groups.
Recombinant human interferon α2b vaginal effervescent tablets have significant therapeutic effects, as they alleviate inflammatory reactions, regulate immune indicators, and are worthy of clinical application and promotion.
2. Yu L, Majerciak V, Zheng ZM. HPV16 and HPV18 Genome Structure, Expression, and Post-Transcriptional Regulation. Int J Mol Sci. 2022;23(9):4943.
3. Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40(5):602-8.
4. Oyouni AAA. Human papillomavirus in cancer: Infection, disease transmission, and progress in vaccines. J Infect Public health. 2023;16(4):626-31.
5. Loopik DL, Bentley HA, Eijgenraam MN, IntHout J, Bekkers RLM, Bentley JR. The Natural History of Cervical Intraepithelial Neoplasia Grades 1, 2, and 3: A Systematic Review and Meta-analysis. J lower Genital Tract Dis. 2021;25(3):221-31.
6. Hoffman SR, Le T, Lockhart A, Sanusi A, Dal Santo L, Davis M, et al. Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review. Int J Cancer. 2017;141(1):8-23.
7. Anastasiou E, McCarthy KJ, Gollub EL, Ralph L, van de Wijgert J, Jones HE. The relationship between hormonal contraception and cervical dysplasia/cancer controlling for human papillomavirus infection: A systematic review. Contraception. 2022;107:1-9.
8. Galli V, Mancino P, Santangelo G, Vasta A, Giannini A, D’Oria O, et al. Loop electrosurgical excision procedure and cold knife conization: which is the best? A large retrospective study. Ital J Gynaecol Obstet. 2022;34(2):120-5.
9. Osmałek T, Froelich A, Jadach B, Tatarek A, Gadziński P, Falana A, et al. Recent advances in polymer-based vaginal drug delivery systems. Pharmaceutics. 2021;13(6):884.
10. Yu L, Wang Y. Effect of recombinant human interferon α2b vaginal effervescent capsules on the vaginal microenvironment and prognosis of patients with CIN complicated with HPV infection after LEEP/CKC. J Bengbu Med University. 2025;50(4):469-72.
11. Fu J, Ren Q, Han Y. Clinical study of Modified Ermiao Granules activating AIM2 inflammasome-mediated pyroptosis to clear HR-HPV and ameliorate LSIL. Europ J Gynaecological Oncol. 2024;45(5):107.
12. He C, Song C, Li M, Ma W, Sun S. Meta-analysis of the effect and safety of recombinant human interferon α-2b combined with Baofukang suppository in the treatment of HPV infection. Am J Transl Res. 2022;14(11):7632-42.
13. Zhang Y, Wang J, Zhang R, Lei F, Lai S. Application Value of Detection of High-Risk HPV Infection in Early Cervical Cancer Patients in Disease Diagnosis and Prognosis Evaluation. Clin Laboratory. 2020;66(12):2449.
14. Bakhsh A, Moyes D, Proctor G, Mannocci F, Niazi SA. The impact of apical periodontitis, non‐surgical root canal retreatment and periapical surgery on serum inflammatory biomarkers. Int Endodontic J. 2022;55(9):923-37.
15. Aljabr W, Al Amari A, Abbas B, Karkashan A, Alamri S, Alnamnakani M, et al. Evaluation of the levels of peripheral CD3+, CD4+, and CD8+ T cells and IgG and IgM antibodies in COVID-19 patients at different stages of infection. Microbiol Spectrum. 2022;10(1):e00845-21.
16. Liu Y. Effect of Recombinant Human Interferon α-2b Vaginal Effervescent Tablet Combined with Microwave in the Treatment of Chronic Cervicitis Complicated with HPV Infection and Its Influence on Vaginal Microenvironment Factors. Reflexol Rehabilitation Med. 2024;5(17):65-7.
17. Mohammadi A, Lotfi E, Karamali F, Golab F, Barati M. Development and validation of a multiplex qPCR method for identification of high-risk genotypes of human papillomavirus. Infect Agents Cancer. 2025;20(1):15.
18. de Beurs E, Carlier I, van Hemert A. Psychopathology and health-related quality of life as patient-reported treatment outcomes: evaluation of concordance between the Brief Symptom Inventory (BSI) and the Short Form-36 (SF-36) in psychiatric outpatients. Quality Life Res. 2022;31(5):1461-71.
19. Bonab FR, Baghbanzadeh A, Ghaseminia M, Bolandi N, Mokhtarzadeh A, Amini M, et al. Molecular pathways in the development of HPV-induced cervical cancer. EXCLI J. 2021;20:320.
20. Bruno MT, Cassaro N, Bica F, Boemi S. Progression of CIN1/LSIL HPV persistent of the cervix: actual progression or CIN3 coexistence. Infect Dis Obstetrics Gynecol. 2021;2021(1):6627531.
21. Spriggs CC, Blanco LZ, Maniar KP, Laimins LA. Expression of HPV-induced DNA damage repair factors correlates with CIN progression. Int J Gynecological Pathol. 2019;38(1):1-10.
22. Wang D, Cui Y, Zhang W, Fan M, Qiu K, Yan L. Effect of different interventions on the treatment of high-risk human papillomavirus infection: a systematic review and network meta-analysis. Front Med. 2024;11:1274568.
23. Li T, Liu Z, Zhang X, Chen X, Wang S. Therapeutic effectiveness of type I interferon in vulvovaginal candidiasis. Microbial pathogenesis. 2019;134:103562.
24. Zhang Y, Liu J, Chen L, Zhao S, He H, Qi Y, et al. Effect of recombinant human interferon α⁃2b effervescent tablets at different periods after cervical cold knife conization on the outcome of HPV infection in HSIL patients. J Guizhou Med University. 2022;47(5):570-80.
25. Priya P, Kumar A, Ghosh AK, Chauhan R, Kumar R, Kumar D. Unveiling the effect of Inflammatory Cytokines TNF-α, IL-6, and IL-1β in Breast Cancer prevalence and progression. Chem Biol Lett. 2025;12(1):1254-.
26. Zhang E, Ding C, Li S, Zhou X, Aikemu B, Fan X, et al. Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy. Biomarker Res. 2023;11(1):28.
27. Li J, Jin H, Sun Y, Wang C, Chen H, Gong S, et al. Reconnoitering correlation between human papillomavirus infection-induced vaginal microecological abnormality and squamous intraepithelial lesion (SIL) progression. BMC Women's Health. 2024;24(1):5.
28. Li J, Jiang L, Wang C, Meng J, Wang H, Jin H. Investigation of the relationship between the changes in vaginal microecological enzymes and human papillomavirus (HPV) infection. Medicine. 2024;103(6):e37068.
29. Zhao J, Li C, Chen W, Gao J, Ma W, Wang Y, et al. Efficacy of recombinant human interferon α-2b combined with cervical loop electrosurgical excision procedure in the treatment of cervical precancerous lesions. Europ J Gynaecological Oncol. 2025;46(2):92-8.
| Files | ||
| Issue | Articles in Press | |
| Section | Original Article(s) | |
| Keywords | ||
| Cervical intraepithelial neoplasia Human papillomavirus Immune response Inflammatory markers ecombinant human interferon α2b | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
